The Global Achondroplasia Treatment Market Is Witnessing High Demand Owing To the Rise of the Condition and the Focus of the Key Market Players on Discovering Advanced Medical Technologies
The main goals of achondroplasia treatment are reduction in hypertrophy, sparing of bone formation, prevention of secondary fractures, and normalization of growth. Achondroplasia treatment options for this disease include surgical procedures, drug therapy including metformin, combination therapy with anti-angiogenesis drugs, and anti-ischemia drugs such as topical immunomodulators. Drug therapy is used mainly to suppress the activity of human growth hormone (HGH), which is responsible for the increased rate of growth in a human fetus. Other drugs used include insulin, oral hypoglycemic agents, calcium channel blockers, oral stimulants, anti-cancer drugs, steroidal compounds androgens, and aminophylline.
Surgical achondroplasia treatment can be performed for three major reasons, namely, long-standing deformity caused due to short stature or congenital short stature, correction of joint deformities caused due to malformation of the vertebrae, and correction of short stature. In most cases, surgery is required for the correction of short stature. Surgery can be performed as a revision procedure to realign the vertebral column and to provide additional height to the short stature affected person. If the defect is caused due to congenital short stature, a spinal disk may have to be removed.
The incidence rate of achondroplasia worldwide is increasing the demand in the global achondroplasia treatment market. For instance, according to NORD (National Organization for Rare Disorders), achondroplasia is one of the most commonly occurring bone abnormalities, and it happens 1 in every 20,000 to 30,000 births. However, in total, this is a rarely occurring disease and can be treated in multiple ways such as limb lengthening, ongoing healthcare, hormone therapy, and surgical treatments. Hence the pharmaceutical companies are also focusing on developing advanced treatments for achondroplasia, which is augmenting the growth of the global achondroplasia treatment market.
Orthopedic surgeons recommend simultaneous treatment for Crohn's disease with anti-inflammatory drugs, corticosteroids, and surgery to correct achondroplasia. Crohn's disease is a serious inflammatory disorder of the digestive tract and it affects most of the body parts including the joints, cartilages, and other internal organs. It is caused due to excessive inflammation of certain body parts, most commonly the joints, and it results in severe dysfunctions and wasting of the affected body parts. Appropriate achondroplasia treatment will prevent further deterioration of these body parts. However, the high cost of the growth hormone treatments is the main factor, which is impacting the global achondroplasia treatment market negatively.
In North America, owing to the rising incidence of dwarfism among individuals there is a significant demand in the global achondroplasia treatment market. For instance, according to Respect Ability, there are around 30,000 individuals in the U.S., who are suffering from dwarfism. Moreover, the advancements in the healthcare system in the region are also propelling the growth of the market. Owing to these factors, there have been some industrial developments in the global achondroplasia treatment market. For instance, in July 2020, a market authorization application for vosoritide was submitted by BioMarin Pharmaceutical Inc. to European Medical Agency.
In-depth Report on Global Achondroplasia Treatment Market by Coherent Market Insights:
Comments
Post a Comment